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Cost-effectiveness analysis of hepatitis A 
prevention in travellers 
Guy Tormans*, Pierre Van Damme *~+ and Eddy Van Doorslaer* 
The advent of new vaccines and the changing epidemiology of hepatitis A call for an update 
of the economic evaluation of costs and benefits associated with the various alternative 
preventative strategies. A decision-tree-based model has been developed which enables the 
calculation of expected costs and expected numbers of hepatitis A virus HA V infections 
based on d(fferent intervention strategies. The model is sufficiently generic to allow Jor the 
evaluation of both population-wide strategies and strategies targeted at particular risk 
groups. An economic analysisJocusing on travellers from Europe to high-endemic countries 
compared a non-intervention strategy to the following three strategies. active immunization 
with HA V vaccine; screening .['or HA V antibodies and vaccinating only susceptibles; 
passive immunization by means of immunoglobulin. The net cost per HA V infection 
prevented proved very sensitive to a number of  important input parameters oj the model. 
These included epidemiological characteristics such as HA V attack rate and prevalence of 
immuniO', behavioural characteristics such as compliance with the vaccination scheme and 
vaccine characteristics such as rate and duration of protection. Our estimated expected 
cost per HA V injection prevented among Belgian travellers to high-endemic countries for 
three weeks per year over ten ),ears amounts to approximately US$4880 .for active 
#nmunization, US$5621 Jor screening followed by vaccination of susceptibles and 
US$29932 jor passive immunization. Although these estimates are clearly sensitive to a 
number of crucial assumptions pertaining to the input parameters of the model, it seems 
safe to conclude that vaccination is more cost-effective than the currently recommended 
passive immunization with immunoglobulin. Screening for antibodies bejore vaccinating 
may be more cost-effective for risk groups having a sufficiently high prevalence of immu- 
nity. 
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INTRODUCTION 
Hepatitis A virus (HAV) infection is a more prevalent 
disease but with a less serious self-limited morbidity and 
a lower disease mortality than that caused by the hepati- 
tis B virus. HAV is an enterically transmitted isease 
with a worldwide distribution, closely related to the level 
of economic development and often occurring in epide- 
mic clusters. In many developed and developing coun- 
tries, disease incidence and prevalence has decreased 
markedly, due to better general hygienic measures. The 
age of infection has shifted to older age groups, also 
related to improving socioeconomic and hygienic con- 
ditions and safer water supplies. As expression of clinical 
disease is highly age-related, the shift of infection to 
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older age groups will increase the number of clinical 
infections. 
From epidemiological studies, several groups at high 
risk for HAV have been recognized. Travellers to ende- 
mic regions, whether for tourism or business, run a signi- 
ficant risk of infection with HAV r. Until recently, the 
only options for prevention were precautionary mea- 
sures and passive immunization with immunoglobulin. 
With the development of hepatitis A vaccines, the poten- 
tial for longer term protection has increased substan- 
tially. 
Three possible strategies for prevention of HAV infec- 
tion in travellers are compared: active immunization 
with the new HAV vaccine; screening for HAV anti- 
bodies first and then vaccinating only susceptibles; pas- 
sive immunization by means of hepatitis A immunoglo- 
bulin. 
METHODS 
The decision-analysis model used to compare each of 
these three strategies to non-intervention is very similar 
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Figure 1 Basic decision tree. U, Decision node; 0, chance node 
to the model that Mulley ef ul. used to evaluate hepatitis 
B prevention strategies?. The aim is to calculate the 
expected incremental net medical care costs per infection 
prevented. This means that for each strategy calculation 
is made as follows: from the additional costs of preven- 
tive intervention, the medical care costs saved as a result 
of prevention are subtracted, and then the total divided 
by the expected number of hepatitis A infections pre- 
vented. 
The structure of the decision problem is depicted in 
Figure I. It describes the possibilities of becoming 
infected depending on the strategies chosen and the asso- 
ciated probabilities of immunity and infection. In Figure 
2, the events occurring after the decision to vaccinate are 
shown. The model is flexible enough to allow for evalu- 
ation of both population-wide strategies and strategies 
targeted at particular risk groups. This evaluation 
focuses only on travellers. The calculation of the 
expected costs and expected numbers of infections under 
each strategy are dependent on the input data. These are 
based on the best estimates available in the literature and 
on epidemiological surveys organized in Belgium. 
INPUT DATA AND ASSUMPTIONS 
Epidemiology 
The target group at risk is assumed to consist of 1000 
Belgian travellers to an endemic country. At a mean age 
of 40 years, the prevalence of HAV antibodies is esti- 
r Protection Onlv 
Vaccination 
I / 
flgure 2 Vaccination tree 
mated at 40%*, implying that 400 of these travellers were 
naturally immune due to an earlier infection’-4. Estimates 
of attack rates in travellers vary with the destination. The 
annual attack rate of HAV in susceptibles travelling to 
endemic countries is estimated to be 3.6% during their 
stay abroad. This figure is based on Steffen’s estimated 
l Vranckx and Muylle4 report a 88% prevalence of HAV anti- 
bodies in blood donors of this age group but other recent 
European figures suggest a lower figure of z 40% among 
travellers3,5. In the sensitivity analysis, the impact of a chang- 
ing prevalence rate will be assessed. 
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Table 1 Vaccination strategy: assumptions 
Dose Compliance Duration of Protection 
(%) protection (years) rate (%) 
First 100 1 90 
Second 60 2 98 
Booster 50 10 99 
average monthly attack rate fox" business people and 
tourists travelling under reasonably good hygienic con- 
ditions (R. Steffen, personal communication, 1992). The 
annual risk of HAV infection while at home is estimated 
to be only 0.3%, based on Fr6sner's estimate for Ger- 
many ('. In reality, travel patterns are very diverse. For 
simplicity, we have assumed that all travellers in this 
target group annually spend a period of 19 consecutive 
days in an endemic ountry with a time span of 10 years 
of travel. 
Clinical course of HAV infection 
It is well known that the development of symptoms 
following HAV infection is strongly related to age. We 
have assumed that at the age of 40, 10% of all infections 
will be asymptonaatic 7,s.For symptomatic nfections, we 
have distinguished between mild, moderate, severe and 
fulminant hepatitis (Figure 3). This distinction was based 
on the way in which these various manifestations are 
being treated. Interviews with an expert panel of general 
practitioners and hepatologists resulted in the following 
distribution: mild, i.e. only treated by the general practi- 
tioner (GP): 50%; moderate, i.e. referred by the GP to 
the hepatologist: 30% of all symptomatic infections; 
severe, i.e. requiring hospitalization: 19.9%; and only 
0.1% resulted in fulminant hepatitis. This distribution 
comes close to that reported by Hadler and PurcelP. No 
chronic hepatitis A carrier states are assumed but bi- 
phasic infections (relapses) do occur. Because it has been 
suggested that relapse rates vary inversely with the sever- 
ity of the infection, we have assumed relapse rates of 9, 7 
and 2% after a mild, moderate and severe HAV infection 
respectively "'.~. 
Estimated costs of treatment 
Calculations of expected costs of treating HAV infec- 
tions are based on a questionnaire sent to GPs and 
hepatologists and an analysis of the records of hospita- 
lized patients. Medical care cost data are presented in 
US$ but reflect Belgian 1991 health-care price levels. 
Details of the costings can be found in Tormans ctal.': 
Average costs of treating mild, moderate and severe 
hepatitis were estimated at US$330,420 and 2144 respec- 
tively. Due to a lack of case records t\)r patients with 
fulminant hepatitis A, we have arbitrarily estimated that 
the costs of treating these patients would be tenfold the 
costs of treating severe hepatitis. Costs of treating relaps- 
ing hepatitis were estimated at US$420. The time span 
for the model is 10 years and all costs in future years were 
discounted to their present value using a discount rate of 
5%. 
INTERVENTION STRATEGIES  
Vaccination 
This strategy aims at active immunization of the entire 
target group with HAV vaccine. However, because the 
vaccine is administered in two doses and a booster (at 0, 
I and 12 months), compliance -and  therefore also pro- 
tection may be less than complete. We have assumed 
that 100% will receive the first dose, but only 60% will 
come for the second dose and 50% for the booster (see 
Tabh, 1). The rate and duration of protection with only 
one dose, with two doses and with the full schedule are 
estimates based on the currently available evidence on 
seroconversion rates ~ 3,14. 
The costs of vaccination are estimated to be US$24 for 
one dose plus US$15 administration costs. 
Screening and vaccination 
To avoid injecting expensive vaccine into immune indivi- 
duals, screening for HAV antibodies can be considered. 
The HAV antibody screening test has high sensitivity 
(99%) and specificity (99%) rates~L Assuming that two 
visits to a physician are needed to obtain blood and 
interpret he test results, the total cost of screening per 
case is estimated at US$43. Compliance to the vaccina- 
tion schedule for those found susceptible after screening 
is assumed to be identical to the compliance of those 
vaccinated without prior screening (see above). 
Passive immunization 
At present, the recommended prevention strategy for 
persons travelling to high endemic regions is passive 
immunization with immunoglobulin. The protection rate 
is estimated to be 85% ">~ and protection lasts for 3 
months. Also, as estimated for active immunization, 
compliance may be incomplete in the sense that indivi- 
duals may not always be willing or able to obtain an 
immunoglobulin jection before each trip. We have esti- 
mated compliance at ~ 50% by assuming that the entire 
target group receives passive immunization for the first 
five years but not for the next five years. Unit costs for 
passive immunization, i.e. the purchase and administ- 
ration of one dose, is estimated at US$41. 
RESULTS 
For each of the three strategies, the expected number of 
infections and the expected costs incurred have been 
calculated using the baseline assumptions. Comparison 
to the 'doing nothing" strategy allows the computation of 
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each strategy's cost-effectiveness, i.e. the net medical 
costs per infection prevented. Table 2 illustrates that the 
total costs are lowest when no preventative action is 
taken, but that, on average, 27.7 per 1000 travellers will 
acquire an HAV infection. Vaccination of all 1000 travel- 
lers reduces this number to 12.6 per 1000 at a total net 
medical expense of US $89 321. It is mainly the imperfect 
compliance that prevents the infection rate from reach- 
ing zero. Screening before vaccination leads to a margi- 
nally higher infection rate (12.8 per 1000), mainly 
because of the 1% false-positive individuals that remain 
susceptible but are not vaccinated. Also the costs for 
screening and vaccinating only susceptibles turn out to 
be higher than for immediate vaccination of the entire 
group. Finally, passive immunization of travellers yields 
the highest overall cost and the highest infection rate of 
the three prevention strategies. The elevated numbers are 
due to the lower protection rate associated with the 
immunoglobulin (85%) and to the compliance problem 
suspected to occur after the fifth year. 
Given these costs and effects, it is not surprising that 
the vaccination strategy ields the lowest cost per infec- 
tion prevented (US$4880). With the screening strategy, it
costs US$5621 to prevent an HAV infection, while the 
cost-effectiveness ratio for passive immunization is about 
six times that of the vaccination strategy (US$29 932). 
Obviously, these baseline results are critically dependent 
on some of the data assumptions made in the model. The 
following section explores the sensitivity of these results 
to changes in the baseline data assumptions. 
Sensitivity analysis 
Table 3 presents the effects of the vaccination strategy on 
the cost-effectiveness ratio (CER) when some of the basic 
assumptions are varied. First, it is shown that the CER 
increases when exposure to HAV risk is reduced and vice 
versa. The costs of preventing HAV infections increase 
when the travel frequency or the duration of the stay 
abroad is reduced. Second, it is obvious that vaccination 
becomes more cost-effective when compliance is higher 
or the price of the vaccine is lower. The CER is relatively 
insensitive to the costs of treating HAV infections. Even 
a tripling of the baseline cost estimates does not reduce 
the CER in a meaningful way (only 24%). Of greater 
importance are the estimated prevalence of immunity 
(which increases the waste of vaccine in non-susceptibles) 
and the attack rate for a particular travel destination 
(which increases the risk of infection). It is clear that the 
availability of more reliable or more specific estimates on 
each of the parameters can substantially improve the 
confidence in the baseline cost-effectiveness re ults. 
Table 2 Cost-effectiveness of HAV prevention: baseline results 
Strategy Infections per Cost (US$) Cost effectiveness 
1000 travellers ratio, (US$) 
Doing nothing 27.7 15 576 - 
Vaccination 12.6 89 321 4 880 
Screening and 12.8 99 389 5 621 
vaccination 
Passive 21.9 198 091 29 932 
immunization 
a The cost effectiveness ratio (CER) is defined as the costs incurred to 
prevent one HAV infection under each intervention strategy, compared to 
doing nothing 
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Table 3 Sensitivity analysis: costs per infection prevented by the 
vaccination strategy compared to doing nothing 
Variable Low value High value 
Input data cost (US$) Input data Cost (US$) 
Frequency of travel 19 days for 1 7138 19 days for 4880 
year 10 years 
Duration of stay 1 week for 10 6460 6 months for 888 
years 10 years 
Booster compliance 0% 14052 100% 3732 
Vaccine price $US16 3760 US$32 6000 
Treatment costs Baseline 4880 Baselinex 3 3729 
Prevalence of 0% 2698 75% 12518 
immunity 
Attack rate abroad 3% 5255 6% 2906 
Indirect costs US$65 per 3453 US$194 per 602 
day lost day lost 
Secondary attack 0% 4880 100% 2236 
rate 
Model extensions 
The indirect costs and secondary attack rate data in 
Table 3 illustrate the effects of two extensions of the basic 
model. So far we have only been concerned with the 
direct costs of intervention, i.e. the medical care costs of 
prevention and treatment. There are, however, also 
indirect costs associated with HAV infections in terms of 
work-related losses due to illness. From the responses of 
GPs and hepatologists, we have estimated the average 
number of work loss days due to mild, moderate and 
severe infection. Table 3 shows the cost-effectiveness 
ratios for vaccination when these work days lost are 
priced by a low estimate (US$65) and a high estimate 
(US$194). Assuming a high cost per day lost, the cost 
savings as a result of vaccination do not outweigh the 
costs of prevention. 
A second extension of the model deals with the issue of 
horizontal transmission. It seems fair to argue that the 
vaccination of these 1000 travellers also prevents an 
(unknown) number of secondary infections through hor- 
izontal transmission to personal contacts. In the baseline 
model, this secondary attack rate was implicitly assumed 
to be 0%. It is shown that the CER from vaccination is
reduced by > 50% when the secondary attack rate is 
assumed to be 100%, i.e. when it is assumed that every 
HAV infected traveller will, on average, transmit the 
infection to one other person. 
Threshold analysis 
The cost-effectiveness ranking of the prevention alterna- 
tives can vary with the input data assumptions. In parti- 
cular, the comparison of screening versus vaccination is
very sensitive to the prevalence of HAV antibodies in the 
target population. Figure 4 shows the cost-effectiveness 
of both alternatives as a function of the prevalence of 
immunity. It can be seen that above the immunity thres- 
hold level of 55%, screening becomes more cost-effective 
than vaccination, keeping all other assumptions con- 
stant. This kind of threshold analysis can be useful in the 
search for the most cost-effective HAV prevention stra- 
tegy for different arget groups. 
CONCLUSIONS 
By means of a decision-tree-based model, the cost-effec- 
tiveness was analysed of three HAV prevention strategies 
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Threshold analysis for the prevalence of HAV antibodies. 
• , Vaccination; +- -+,  Screening 
for travellers to countries with high endemicity was ana- 
lysed. Vaccination proved to be more cost-effective than 
the currently recommended passive immunization. How- 
ever, vaccination does not save health-care costs. Under 
the baseline assumptions, the net cost per infection pre- 
vented is estimated at US$4880. The baseline cost-effecti- 
veness ratios vary substantially with input data assump- 
tions about travel behaviour, compliance with the 
immunization schedule and risk exposure, but are relati- 
vely insensitive to HAV infection treatment costs. 
Extending the model, by taking into account indirect 
costs and secondary attack rates through horizontal 
transmission, reduces the cost per infection prevented 
but does not make prevention a cost-saving item. Screen- 
ing for HAV antibodies and then vaccinating suscept- 
ibles only becomes a more cost-effective strategy at high 
prevalence rates of immunity. 
Further investigation is required on some of the cru- 
cial input parameters to the model to increase the reliabi- 
lity of the outcomes and to extend its usefulness to the 
evaluation of HAV prevention strategies for other risk 
groups than travellers. 
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